October 20, 2026, 12pm-1pm ET
Sleep for resilience: Translational insights from mouse models to human dementia with Brianne Kent
Sleep disturbance is a common symptom of Alzheimer’s disease (AD) and reduced slow-wave sleep (SWS) is linked to increased risk of dementia. Our translational work spanning mouse models and human cohorts is evaluating sleep as a modifiable target for promoting resilience to dementia. In a mouse model of AD, chronic administration of the SWS-enhancing antidepressant trazodone reduced markers of AD neuropathology, in addition to consolidating sleep and improving short-term and long-term memory. In humans, we have been studying how sleep is associated with cognitive performance and dementia risk in the Brain Resilience Study, a new open-science initiative integrating sleep, cognition, neuroimaging, and psychosocial data across 1,000+ older adults to advance early, personalized, and equitable dementia prevention.
Please note that registration is required to attend. Click here to register.
Past webinars
What are you looking for?
Culturally grounded, community-based, and self-determined dementia risk reduction research in Northwestern Ontario
September 22, 2026
The role of psychosocial, lifestyle, and health factors in cognitive and brain aging
May 19, 2026
“You have to be there”: Emotional labor, cultural ethics, and the realities of Black families of people with dementia in Canada during COVID-19
February 17, 2026
Caring for the family caregiver: Lived experiences of family caregivers and mindfulness-based interventions for older adult caregivers of persons with dementia
January 20, 2026
Developing Dementia Decoded: Acute Care Dementia Strategy at The Ottawa Hospital
December 16, 2025
Using plasma biomarkers to estimate the prevalence of Alzheimer’s Disease pathology in COMPASS-ND
November 17, 2025
Use of lecanemab and donanemab in the Canadian healthcare system: Evidence, challenges, and areas for future research
May 20, 2025
The content of this webinar is based on this scientific review paper: Smith E. et al. (2025), Use of Lecanemab and Donanemab in the Canadian Healthcare System: Evidence, Challenges, and Areas for Future Research. Journal of Prevention of Alzheimer’s Disease.
Visit this page for frequently asked questions about the use of new medications for Alzheimer’s disease in the Canadian healthcare system
Dementia-related apathy: Recent advances in diagnosis and treatment
April 29, 2025
This presentation is based on this scientific review paper: Lanctôt K.L. et al. (2023) Distinguishing apathy from depression: A review differentiating the behavioral, neuroanatomic, and treatment-related aspects of apathy from depression in neurocognitive disorders. International Journal of Geriatric Psychiatry. Feb., 38(2):e5882.
Consult this page for an infographic tool for clinicians on distinguishing apathy from depression in neurocognitive disorders
Brain rhythms, proteinopathy, and neurochemistry along the Alzheimer’s disease continuum
February 5, 2025
Food on the brain: Nutrition in Indigenous communities
December 10, 2024
Navigating risk-taking in the presence of anosognosia: Decision-making capacity challenges in Alzheimer’s disease
December 3, 2024
Modest dietary carbohydrate restriction to sustain healthy cognitive aging
October 8, 2024
